PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Monotherapy - Market size and forecast 2018-2023 • Combination therapy - Market size and forecast 2018-2023 • Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Expansion of research indications • Special drug designations • Increasing awareness about cancer PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca Plc • Bristol-Myers Squibb Co. • Ono Pharmaceutical Co. Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Monotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Monotherapy - Year-over-year growth 2019-2023 (%) Exhibit 22: Combination therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Combination therapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Europe - Year-over-year growth 2019-2023 (%) Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Asia - Year-over-year growth 2019-2023 (%) Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 35: ROW - Year-over-year growth 2019-2023 (%) Exhibit 36: Key leading countries Exhibit 37: Market opportunity Exhibit 38: Impact of drivers and challenges Exhibit 39: Vendor landscape Exhibit 40: Landscape disruption Exhibit 41: Vendors covered Exhibit 42: Vendor classification Exhibit 43: Market positioning of vendors Exhibit 44: AstraZeneca Plc - Vendor overview Exhibit 45: AstraZeneca Plc - Business segments Exhibit 46: AstraZeneca Plc - Organizational developments Exhibit 47: AstraZeneca Plc - Geographic focus Exhibit 48: AstraZeneca Plc - Key offerings Exhibit 49: AstraZeneca Plc - Key customers Exhibit 50: Bristol-Myers Squibb Co. - Vendor overview Exhibit 51: Bristol-Myers Squibb Co. - Business segments Exhibit 52: Bristol-Myers Squibb Co. - Organizational developments Exhibit 53: Bristol-Myers Squibb Co. - Geographic focus Exhibit 54: Bristol-Myers Squibb Co. - Key offerings Exhibit 55: Bristol-Myers Squibb Co. - Key customers Exhibit 56: Ono Pharmaceutical Co. Ltd. - Vendor overview Exhibit 57: Ono Pharmaceutical Co. Ltd. - Business segments Exhibit 58: Ono Pharmaceutical Co. Ltd. - Organizational developments Exhibit 59: Ono Pharmaceutical Co. Ltd. - Geographic focus Exhibit 60: Ono Pharmaceutical Co. Ltd. - Key offerings Exhibit 61: Ono Pharmaceutical Co. Ltd. - Key customers Exhibit 62: Validation techniques employed for market sizing Exhibit 63: Definition of market positioning of vendors

AstraZeneca Plc, Bristol-Myers Squibb Co., and Ono Pharmaceutical Co. Ltd.